Clinics of oncology最新文献

{"title":"Leiomyosarcoma of Stomach","authors":"Batyrbekova K, Galiakbarova A, Ualikhanov A","doi":"10.47829/COO.2021.3505","DOIUrl":"https://doi.org/10.47829/COO.2021.3505","url":null,"abstract":"1. Abstract Leiomyosarcoma is a malignant tumor that forms from smooth muscle tissue. The average age of the disease is 40 to 60 years. The tumor is characterized by rapid progressive growth with a high degree of malignancy, while it often recurs and at the early stages it metastases to other organs. Of the sarcomas in the stomach, the most common is leiomyosarcoma, which accounts for 1-3% of all stomach tumors. The tumor rarely grows into neighboring organs and tissues; it does not metastasize to the lymph nodes, but it does metastasize to the liver and lungs. Most of the cases described as leiomyosarcomas were actually gastrointestinal stromal tumors and therefore only 13 cases of true gastric leiomyosarcomas have been published in the English-language literature since the 2000s. In this article, we presented our first event on the diagnosis of gastric leiomyosarcoma. 2. Introduction Due to a small percentage of these tumors, there is still no standard treatment protocol for these patients, but standard gastric resection is used. The main method in the chain of diagnostic measures is morphological (histological and immunohistochemical) examination of the material after a tumor biopsy [1]. All leiomyosarcomas can be divided into the following morphological variants: spindle cell (traditional), pleomorphic, epithelioid, myxoid, and inflammatory [2]. Histological examination of the tumor, currently, in the vast majority of cases, does not allow the pathologist establish an accurate morphological diagnosis. Currently, immunohistochemical treatment is widely used all over the world. 5 research using mono and polyclonal antibodies [3]. With the advent of immunohistochemistry and its increasing availability for the diagnosis of stromal tumors, the frequency of leiomyosarcomas has significantly decreased. Currently, gastric leiomyosarcoma is an exceptionally rare tumor. We report the first case in the kazakh endoscopy society and kazakh oncology of gastric leiomyosarcoma revealed with metastatic disease of brain and lung. 3. Case Report Patient S. 68 years old, was admitted to the paid department for further examination with a diagnosis: MTS of both lungs without a primary lesion. Volume formation of the left parietal-occipital region. Convexital meningioma? Chronic calculous cholecystitis. Bronchial asthma, persistent course, moderate severity. Bronchiectasis. Arterial hypertension 3 St, risk 3. It is aimed at endoscopic check-up to identify the primary focus (bronchoscopy, gastroscopy, colonoscopy). During gastroscopy – at the level of the middle part of the stomach body in the area of large curvature, an oval-shaped formation was revealed, raised with a depression and ulcerative deformity in the center, at the bottom of the detritus is white, measuring 1.8 X1,2x0.5 cm, on the surface and along the edges of the vascular pattern is uneven, bizarre, there are avascular areas, the surface pattern is structureless, during biopsy the tissue is stony consi","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81020874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvascular Head & Neck reconstruction in an Institution During its formative Stage","authors":"Rout Sk, Giri Sk, P. R, Sahu Rk, S. S., M. M","doi":"10.47829/coo.2021.5303","DOIUrl":"https://doi.org/10.47829/coo.2021.5303","url":null,"abstract":"","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72804511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aortic Replacement for Retroperitoneal Tumors in Children","authors":"R. C. Ribeiro, Simone de Campos Vieira Abib","doi":"10.47829/coo.2021.5601","DOIUrl":"https://doi.org/10.47829/coo.2021.5601","url":null,"abstract":"1. Abstract Retroperitoneal tumors may involve the abdominal aorta. Sometimes, these tumors are unresponsive to adjuvant therapy. The total resection is a challenge mainly for vascular reconstruction in children. Then, we report three cases of aortic replacement in children with retroperitoneal tumors. Case 1: an eight-year-old girl presenting with a ganglioneuroma involving the aorta. The tumor was resected with an abdominal aorta segment, which was replaced by an aortoaortic prosthesis. Case 2: a 13-year-old boy was presented with a paraganglioma involving the aortic bifurcation, requiring resection and replacement by aortoiliac bypass. Case 3: an 11-year-old girl with abdominal neurofibromatosis. During the resection, the aorta and left iliac artery were replaced by an aortoiliac graft. Resection of a segment of the aorta and revascularization using a prosthesis is feasible in retroperitoneal tumors in children, but the long-term results are unknown. 2. Introduction Retroperitoneal tumors in children may involve or surround the abdominal aorta and its main branches. Such vascular involvement leads to challenging surgical procedures and may be considered unresectable. When large tumors involve major vascular trunks and do not respond to chemotherapy, resection of the tumor with replacement of the aorta may be an alternative. Replacement of the abdominal aorta in children is a complex procedure that is rarely performed. In children, synthetic grafts are limited by a concern for late infection and lack of potential growth. There are few reports on this in the literature. We report three cases of children with retroperitoneal tumors, in which replacement of the aorta was needed in order to resect the tumor. 3. Patients and Methods Cases came from two reference institutions for pediatric oncology, pediatric surgical oncology, and vascular surgery. Three cases in which tumor resection was performed with replacement of the aorta or its branches were found, who underwent three procedures. 4. Case 1 An eight-year-old girl, presented with abdominal mass for 10 months and deficit of growth for two years. Ultrasound (US) and computed tomography (CT) revealed a mass involving the aorta, celiac trunk, mesenteric artery, and left renal hilum (Figure 1). Initial biopsy revealed a ganglioneuroma. Due to tumor dimension and suspecting that there might be concomitant malignant parts within the tumor that might not have been not sampled at the initial biopsy, a partial resection (debulking) procedure was indicated. During this procedure, the aorta and superior mesen-","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"40 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72480531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Environmental Factors Caused by Exposure to Air Pollution in Yeosu Industrial Complex: Analyzing Google Trend Trends in Cancer Generation Through Big Data","authors":"K. Choi, Bu-Soon Son, Wonho Yang","doi":"10.20944/preprints202008.0053.v1","DOIUrl":"https://doi.org/10.20944/preprints202008.0053.v1","url":null,"abstract":"Depending on the characteristics of the industrial area, toxicity evaluation of human body, risk assessment and health impact assessment may directly cause cancer due to air pollution. Environmental data collection is from August 2018 to January 31, 2019, and the average, minimum, and maximum values of air pollution data respectively. According to the global data on global trends using the Big Data, high blood pressure is confirmed at 33rd place in the world, and myocardial infarction among the environmental diseases is confirmed to be lower than Korea. Disease that occurred in Jeolla province industrial complex considering the characteristics of our country was identified as representative. Air pollutants are considered to be the causes of allergic diseases in Korea. PM10 was found to be higher than the control area (28.8804348 (㎍ / ㎥), 31.7065217 (㎍ / ㎥) and 32.8532609 (㎍ / ㎥). The mean concentrations of PM2.5 in the middle and high exposure areas were lower than those of the control areas, but the highest in the intermediate exposure areas was 16.5978261 (㎍ / ㎥), 16.1086957 (㎍ / ㎥) and 17.1847826 (㎍ / ㎥) respectively. The relationship between the major variables of environmental exposure in Yeosu was confirmed to be correlated with high blood pressure, chronic obstructive pulmonary disease (COPD), bronchitis, cerebrovascular, diabetes, thyroid disease, sinus infection, anemia and pneumonia.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89782756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Principles of Cancer Screening","authors":"Petrikovsky Bm","doi":"10.47829/coo.2020.3403","DOIUrl":"https://doi.org/10.47829/coo.2020.3403","url":null,"abstract":"In 1968, Wilson and Jungner (WJ) put together the following criteria of screening approved by the World Health Organization (WHO) [1]. 1. The condition sought should be an important health problem. 2. There should be an accepted treatment for patients with recognized disease. 3. Facilities for diagnosis and treatment should be available. 4. There should be a recognizable latent or early symptomatic stage. 5. There should be a suitable test or examination. 6. The test should be acceptable to the population. 7. The natural history of the condition, including development from latent to declared disease, should be adequately understood. 8. There should be an agreed policy on whom to treat as patients. 9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole. 10. Case-finding should be a continuing process and not a \"once and for all\" project. Recently, the WHO officers have updated the WJ criteria taking into account recent developments in genetic and genomic medicine, among many other factors. Synthesis of emerging screening criteria proposed over the past 40 years 1. The screening program should respond to a recognized need. 2. The objectives of screening should be defined at the outset. 3. There should be a defined target population. 4. There should be scientific evidence of screening program effectiveness. 5. The program should integrate education, testing, clinical services and program management. 6. There should be quality assurance, with mechanisms to minimize potential risks of screening. 7. The program should ensure informed choice, confidentiality and respect for autonomy. 8. The program should promote equity and access to screening for the entire target population. 9. Program evaluation should be planned from the outset. 10. The overall benefits of screening should outweigh the harm. The perfect example of successful screening is cervical cancer (CC), a “fairytale” of gynecological oncology. • The HPV virus is a known cause of cervical dysplasia and cancer. CC, therefore, is a sexually transmitted disease. • CC has known precursors – various degrees of cervical dysplasia.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82436150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Day After","authors":"Bertolini A, Menatti E, Maiolani M, Cubeddu A, Barbonetti C, Stiglich F, Cattalini N, Fregoni V, Del Barba","doi":"10.47829/coo.2020.3402","DOIUrl":"https://doi.org/10.47829/coo.2020.3402","url":null,"abstract":"Bertolini A1*, Menatti E1, Maiolani M1, Cubeddu A1, Barbonetti C2, Stiglich F2, Cattalini N3, Fregoni V4 and DEL Barba5 1Department of Oncology, ASST della Valtellina e Alto Lario, Sondrio Hospital, via Stelvio, 25 Sondrio Italy 2Department of Radiotherapy, ASST della Valtellina e Alto Lario, Sondrio Hospital, via Stelvio, 25 Sondrio Italy 3Hospital Direction, ASST della Valtellina e Alto Lario, Sondrio Hospital, via Stelvio, 25 Sondrio Italy 4Department of Breast Unit, Sondalo Hospital, ASST della Valtellina e Alto Lario, via Zubiani, 33 Sondalo Italy 5SEN, Italian Parliament, Piazza di Monte Citorio, Roma, Italy","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"136 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72468343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Both XELIRI And TEGAFIRI Togetherwith Bevacizumab are Effective for Recurrent or Metastatic Colorectal Cancer: A Real-Life Experience","authors":"Hsu Tc, Liao Pn","doi":"10.47829/coo.2020.3101","DOIUrl":"https://doi.org/10.47829/coo.2020.3101","url":null,"abstract":"Both XELIRI And TEGAFIRI Together with Bevacizumab are Effective for Recurrent or Metastatic Colorectal Cancer: A Real-Life Experience Hsu TC and Liao PN Department of Surgery, Division of Colon & Rectal Surgery, Taipei Mackay Memorial Hospital, Taipei, Taiwan ; Department of Medicine, Mackay Medical College, New Taipei City, Taiwan Department of physician, Taipei Mackay Memorial Hospital, Taipei, Taiwan","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80580511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on Ghanem’s New Scientific Discoveries in Physics, Physiology, and Medicine","authors":"Ghanem An","doi":"10.47829/coo.2020.3302","DOIUrl":"https://doi.org/10.47829/coo.2020.3302","url":null,"abstract":"as based on Starling’s forces. ABSTRACT Introduction and objective: To report the new scientific discoveries in physics, physiology and medicine by one author. Materials and methods: Results of my research are summarized. It is based on 2 clinical studies one prospective and the second case series on Hyponatraemia (HN) of The Transurethral Resection of the Prostate (TURP) syndrome. A physics study on porous orifice (G) tube proves Starling’s law is wrong. I reported prospective study on nephroptosis revealing its link with the Loin Pain Haematuria Syndrome (LPHS) and curative surgery for it. Results: Two physics and two physiological discoveries are reported. Acute HN presents as shock during surgery. It is induced by massive gain of sodium-free fluid recognized as Volumetric Overload Shock (VOS). Features of the multiple organ dysfunction syndrome occur, include ARDS, Acute Renal Failure (ARF) and Coma. The prospective study demonstrated volumetric overload is the most significant in patho-aetiology. The case series demonstrated mistaking VOS for a known shock and treating it with further volume expansion cause death. Correct diagnoses as VOS and treating it with hypertonic sodium are lifesaving. The physics study on the G tube demonstrated that proximal, akin to arterial, pressure induces suction not filtration producing the hydrodynamic phenomenon that replaces Starling’s law. The link of LPHS with nephroptosis is demonstrated by the IVU 7 sign. The curative surgery for LPHS is renal sympathetic denervation and nephropexy. Conclusion: Dilution HN presents as shock that is mistaken for known shocks and treated with volume expansion causing death or ARDS. Manifestations include shock, ARDS, ARF and Coma. The correct treatment is hypertonic sodium. Starling s law has proved wrong. The correct replacement is the hydrodynamics of G tube. The puzzle of LPHS was also resolved.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74902243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal Stromal Tumors of the First Jujenal Small Bowel: A Case Report","authors":"Zatir S, Bouazzaoui A, Bouchakour S, Ougerti N, Laouisset S, Abdellaoui K, Larkam T","doi":"10.47829/coo.2020.3405","DOIUrl":"https://doi.org/10.47829/coo.2020.3405","url":null,"abstract":"Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors that are usually located in the stomach or small intestine. Less than 5% of GISTs are located outside the gastrointestinal tract: these are extra gastrointestinal stromal tumors (EGIST) [3,4]. The widely accepted treatment for GISTs and EGISTs is complete resection (R0) when the tumors are not invading or metastasizing. Their treatment is surgical [5]. Currently, if the entity of stromal tumors is well defined, there remains uncertainties as to their classification according to their degree of malignancy involving long-term follow-up of all patients. The aim of this article is to review the therapeutic approach of digestive stromal tumors and to clarify the management after surgical treatment of these patients.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89265760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible Impact of a European Agency for the Strategic Management Against Cancer (EASMAC) on Treatment, Diagnosis and EU Politics","authors":"Melidis C","doi":"10.47829/coo.2020.3204","DOIUrl":"https://doi.org/10.47829/coo.2020.3204","url":null,"abstract":"","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"155 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78135974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}